Trellus Health PLC
TRLS
Company Profile
Business description
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
Contact
19 Stanwell Road
Avon House, Penarth
CardiffCF64 2EZ
GBRSector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.20 | 2.20 | 0.02% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,416.98 | 69.07 | 0.26% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 63,267.63 | 525.06 | 0.84% |
| NZX 50 Index | 13,062.78 | 17.55 | -0.13% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,625.30 | 5.70 | -0.07% |
| SSE Composite Index | 4,218.22 | 3.73 | 0.09% |